Alvotech vs Immunocore
ALVO and IMCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALVO and IMCR compare
Alvotech grew revenue faster over the last twelve months (19.7% versus 13.1% for Immunocore).
Immunocore scores higher on the StockData Score (7 against 3 for Alvotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALVO | IMCR |
|---|---|---|
| Size and price | ||
| Market cap | – | $1.5B |
| Share price | $4.19 | $29.94 |
| Change, 1 year | −25.2% | −15.2% |
| Change, 5 years | −57.8% | −21.4% |
| Beta (5Y) | 0.43 | 0.69 |
| Employees | 1,000 | 524 |
| StockData Score | ||
| Total score | 3 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 0 | 3 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 3.6× |
| P/B | – | 3.7× |
| FCF yield | – | −1.2% |
| Fair value | – | $31.07 |
| Margin of safety | – | 3.6% |
| Growth | ||
| Revenue growth (TTM) | 19.7% (better) | 13.1% |
| Revenue growth, 5Y average | 54.5% | – |
| Profitability | ||
| Gross margin | 59.8% | 98.9% (better) |
| Operating margin | 13.3% (better) | −6.8% |
| Net margin | – | −7.5% |
| FCF margin | −19.6% | −4.2% (better) |
| Return on equity | – | −7.9% |
| Financial health | ||
| Net debt / EBITDA | 10.02 | – |
| Interest coverage | 0.5× (better) | −2.4× |
| Current ratio | 1.65 | 4.62 (better) |
| Altman Z-score | – | 1.45 |
| Piotroski F-score | – | 3 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 102% |
| Held by insiders | 67.7% | 15.5% |
| Insider net buying, 12 months | – | −$1.9M |
Go deeper
- ALVO stock overview
- ALVO income statement
- ALVO valuation and score
- IMCR stock overview
- IMCR income statement
- IMCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.